tbuckley/cabot-search huggingface dataset:
Consolidation therapy using cyberknife radiosurgery in NSCLC patients with low-volume residual disease upon completion of systemic therapy
Authors: M. P. McLaughlin, R. Bordoni, T. Whitaker, P. Zolty, M. Andrews, T. Still, J. Vanapalli, K. Haile
Journal: Journal of Clinical Oncology (2007)

18213 Background: Pts with unresectable IIIB and IV NSCLC with PS 0–1 are usually treated with chemotherapy (CH) ± targeted therapy (TT) with overall survival (OS) improvement. Upon completion, standard of care is observation. Pts eventually progress within 9 to 12 months. If still in good PS, they are treated with salvage CH or TT; otherwise, they receive palliative care. We evaluated 12 patients with PR to initial therapy, found to have small volume residual disease (SVRD) defined as one or two sites to receive “consolidation” local therapy with Cyberknife Radisurgery (CRS). Methods: Since September 2006, 12 pts with NSCLC, stage IIIB unresectable (3) or IV (9), median age 64 (range 61–78), adenocarcinoma (7), squamous cell carcinoma(5), 9 males, all ECOG PS 0–1, were treated with induction CH (carboplatin/paclitaxel ± bevacizumab, cisplatin/gencitabine) with PR. CT/PET imaging showed SVRD. Eight patients had only one site; four had 2. These patients received CRS consolidative therapy to the following areas: lung-9, mediastinal node - 3, adrenal-2, liver-2. CRS dose depended on the disease site. Peripheral lung lesions - 54 Gy in 3 fractions (fx); medistinal lesions - 50 Gy in 4 fx; adrenal - 24 Gy in 3 fx and liver - 16 Gy. in 1 fx. The primary end point was efficacy (response rate, time to progression in or out of the radiosurgical fields, and OS) compared with historical matched controls. The secondary end point was safety and tolerability of CRS. Results: After a median follow up period of 65 days, all evaluable pts are still alive and without clinical or radiological (CT/PET) evidence of disease progression in or outside the sites of CRS. The treatment was well tolerated with no Grade 3–5 complications. PS remained 0–1 in all patients. Conclusions: Patients with advanced NSCLC benefit from systemic therapy with symptoms control and improved QoL and OS. Upon completion of therapy, observation is the current standard or care. Patients with good PS and SVRD tolerated CRS consolidation therapy remarkably well and may benefit with added symptoms control, improved TTP and even OS. At the June meeting efficacy and toxicity data of a projected population of 30+ patients, with a medial follow up of 8 months, will be presented. No significant financial relationships to disclose.
Interleukin-4 and -13 Induce Upregulation of the Murine Macrophage 12/15-Lipoxygenase Activity: Evidence for the Involvement of Transcription Factor STAT6
Authors: Dagmar Heydeck, Leo Thomas, Kerstin Schnurr, Frank Trebus, William E. Thierfelder, James N. Ihle, Hartmut Kühn
Journal: Blood (1998)
Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine.
Authors: K Barton, R A Larson, S O'Brien, M J Ratain
Journal: Journal of Clinical Oncology (1992)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1992.10.11.1821 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 1357112 Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine. K BartonxK BartonSearch for articles by this author , R A LarsonxR A LarsonSearch for articles by this author , S O'BrienxS O'BrienSearch for articles by this author , M J RatainxM J RatainSearch for articles by this author https://doi.org/10.1200/JCO.1992.10.11.1821 PDF "Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine.." Journal of Clinical Oncology, 10(11), p. 1821© 1992 by American Society of Clinical Oncology
Efficacy markers for cisplatin and S-1 in biliary tract carcinoma.
Authors: Yasunari Sakamoto, Hidenori Ojima, Chigusa Morizane, Seri Yamagishi, Hiroko Hosoi, Shunsuke Kondo, Hideki Ueno, Takuji Okusaka, Yae Kanai
Journal: Journal of Clinical Oncology (2015)

334 Background: Gemcitabine (GEM) + cisplatin (CDDP) combination chemotherapy is the first choice for advanced biliary tract carcinoma (BTC). In Japan, the GEM + S-1 therapy has shown promise for the treatment of BTC. Our aim was to investigate the cytotoxic effects of GEM, CDDP and S-1 on BTC cell lines and find an immunohistochemical marker for predicting the efficacy of chemotherapy. Methods: We evaluated the efficacy of GEM, CDDP, and S-1 by means of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay of 17 BTC cell lines. Furthermore, we subdivided the cell lines into sensitive and insensitive groups on the basis of the sensitivity of each drug. Moreover, pairwise studies were conducted using the MTT assay, Bliss additivism model, and Combination Index for analysis. Immunohistochemical expression analysis of excision repair cross-complementation group 1 (ERCC1), thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyltransferase (OPRT), and thymidine phosphorylase (TP) were also performed in each cell line to compare the results of the cytotoxic effects of CDDP and S-1. Results: In the single-agent MTT assays, among the 17 tumor cell lines, 11 were sensitive to GEM, 13 to CDDP, and 11 to S-1. In 5 cell lines, &lt;30% of the cells showed ERCC1 expression; these lines belonged to the CDDP-sensitive group. Conversely, the cell lines with &gt;30% ERCC1-positive cells mostly belonged to the CDDP-insensitive group. CDDP IC 50 correlated with the percentage of ERCC1-positive cells (P &lt;.05). In contrast, none of the immunohistochemical markers could be used to select a cutoff level that would point to the sensitivity to S-1. In pairwise MTT assays (combination therapy), we demonstrated the synergy of GEM with CDDP in 9 tumor cell lines (53%) and the synergy of GEM with S-1 in 4 tumor cell lines(24%). Although 3 cell lines with the synergy of GEM with CDDP showed &lt;30% ERCC1-positive cells, there was no correlation between them. Conclusions: ERCC1 expression in &lt;30% of cells may help to identify CDDP-sensitive tumors; however, it is unknown whether expression of ERCC1 can help to predict efficacy of treatment with GEM + CDDP.
Maternity Care Practices and Breastfeeding Among Adolescent Mothers Aged 12–19 Years — United States, 2009–2011
Authors: Oluwatosin Olaiya, Deborah L. Dee, Andrea J. Sharma, Ruben A. Smith
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

The American Academy of Pediatrics recommends that infants be breastfed exclusively for the first 6 months of life, and that mothers continue breastfeeding for at least 1 year. However, in 2011, only 19.3% of mothers aged ≤20 years in the United States exclusively breastfed their infants at 3 months, compared with 36.4% of women aged 20-29 years and 45.0% of women aged ≥30 years. Hospitals play an essential role in providing care that helps mothers establish and continue breastfeeding. The U.S. Surgeon General and numerous health professional organizations recommend providing care aligned with the Baby-Friendly Hospital Initiative (BFHI), including adherence to the Ten Steps to Successful Breastfeeding (Ten Steps), as well as not providing gift packs containing infant formula. Implementing BFHI-aligned maternity care improves duration of any and exclusive breastfeeding among mothers; however, studies have not examined associations between BFHI-aligned maternity care and breastfeeding outcomes solely among adolescent mothers (for this report, adolescents refers to persons aged 12-19 years). Therefore, CDC analyzed 2009-2011 Pregnancy Risk Assessment Monitoring System (PRAMS) data and determined that among adolescent mothers who initiated breastfeeding, self-reported prevalence of experiencing any of the nine selected BFHI-aligned maternity care practices included in the PRAMS survey ranged from 29.2% to 95.4%. Among the five practices identified to be significantly associated with breastfeeding outcomes in this study, the more practices a mother experienced, the more likely she was to be breastfeeding (any amount or exclusively) at 4 weeks and 8 weeks postpartum. Given the substantial health advantages conferred to mothers and children through breastfeeding, and the particular vulnerability of adolescent mothers to lower breastfeeding rates, it is important for hospitals to provide evidence-based maternity practices related to breastfeeding as part of their routine care to all mothers, including adolescent mothers.
Impact of self-reported performance status on survival in advanced colorectal cancer
Authors: J. Burrows, C. Lammersfeld, S. Dahlk, S. Walker, P. G. Vashi, C. G. Lis, D. Gupta
Journal: Journal of Clinical Oncology (2004)

3761 Background: Patients with advanced cancer are greatly concerned about their ability to carry out the activities of daily living. Eastern Cooperative Oncology Group (ECOG) scale has been widely used to quantify the performance status of cancer patients. ECOG captures patient-derived functional status data on a scale of 0 through 4; 0 being normal with no limitations and 4 being completely disabled and bedridden. The purpose of this investigation was to assess the impact of baseline ECOG scores on survival in patients with advanced colorectal cancer. Methods: A retrospective chart review was performed on a consecutive case series of 233 stages III and IV colorectal cancer patients treated at Cancer Treatment Centers of America at Midwestern Regional Medical Center between January 1995 and March 2001. The patient cohort was divided into 2 categories; newly diagnosed (63) and recurrent disease (170). Patients were also divided into 2 mutually exclusive classes of functional status, good (ECOG scores of 0 to 1) and poor (ECOG scores of 2 to 4). The Kaplan-Meier method was used to calculate survival which was defined as the time interval between date of first patient visit to the hospital and date of death from any cause or date of last contact. The log rank test statistic was used to evaluate the equality of survival distributions across the two ECOG strata. Results: Newly diagnosed patients with good ECOG scores had a median survival of 30.5 months (95% CI, 17.8 to 43.3; n = 47) while those with poor scores had 15.1 months (95% CI, 1 to 29.1; n = 10), the difference being statistically significant (p = 0.01). Similarly, patients with recurrent disease demonstrated a statistically significantly (p = 0.0002) better median survival for good ECOG scores (10.1 months; 95% CI, 8.1 to 12; n = 104) as compared to those with poor ECOG scores (5.1 months; 95% CI, 3.1 to 7.1; n = 53). Conclusions: In this cohort, we found that low ECOG scores (good performance status) versus high ECOG scores (poor performance status) identified patients with better survival outcomes. Further studies need to focus on more extensive investigation of the prognostic importance of the ECOG scores in clinical cancer settings. No significant financial relationships to disclose.
Anti-cancer effects of bisphosphonates in lung cancer cell lines
Authors: C. D. MacDonald, L. M. Pickering, J. L. Mansi, K. W. Colston
Journal: Journal of Clinical Oncology (2004)

7289 Background: Lung carcinoma is one of the most commonly diagnosed cancers worldwide and systemic spread of the primary tumour is common: 80% of lung cancers metastasise to bone and thus may cause significant morbidity. In clinical studies, bisphosphonates (BPs) have been shown to limit the formation and progression of bone metastases in several carcinomas including lung cancer although the mechanisms by which BPs mediate these effects are incompletely understood. It has been demonstrated that BPs have a wide range of direct effects in a number of cancer cell types in vitro including induction of apoptosis and alteration of invasive properties. However there is little data addressing the in vitro effects of BPs in lung cancer cells. This study therefore aimed to determine whether BPs had inhibitory effects in a panel of lung cancer cell lines. Methods: Two nitrogen containing BPs zoledronic acid, (ZOL) and pamidronate (APD), and the non-nitrogen containing compound clodronate (CLOD) were tested against a panel of non-small cell and small cell lung carcinoma cell lines (n=5). Cell viability and number were determined using MTS dye reduction and Sulforhodamine B assay. Apoptosis was assessed by Cell Death ELISA. Relative cleavage of the substrate Ac-DEVD-pNA was used to determine caspase activation. Inhibition experiments were performed with the broad-spectrum caspase inhibitor Z-VAD-FMK. Results: BPs reduced cell viability and number in a concentration and time dependent manner. Cell lines differed in their sensitivity to BPs but ZOL and APD were consistently more potent than CLOD, with LD50s between 10 and >100μM for ZOL and APD but from 500 to >2000μM for CLOD. All BPs induced apoptosis by day three of treatment. Apoptosis induction was associated with caspase activation in all cell lines, to varying degrees, while BP-induced loss of cell viability was partially abrogated by co-incubation Z-VAD-FMK in some cell lines. Conclusions: BPs directly induce apoptosis in human lung carcinoma cell lines by both caspase dependent and independent means. The mechanisms involved in this process may be cell line dependent. This study provides a scientific basis for the clinical effects of BPs in lung cancer. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis (Switzerland)
Is there a relation between asthma associated gene polymorphisms and recurrent wheezing in preschool children? The ADEM study
Authors: Ester M.M. Klaassen, Marieke Quaak, Kim D.G. van de Kant, Quirijn Jöbsis, Onno C.P. van Schayck, Frederik-Jan van Schooten, John Penders, Gerard H. Koppelman, Guillaume van Eys, Edward Dompeling
Journal: European Respiratory Journal (2011)

Background: About 20-40% of preschool children experience wheezing. One in three wheezers will have persistent symptoms after the age of six and develop asthma. It is unknown which gene variants contribute to wheezing.

Aim: To explore the relation between asthma associated single nucleotide polymorphisms (SNPs) and preschool recurrent wheezers.

Methods: We selected 202 recurrent wheezers (ISAAC questionnaire ≥2 wheezing episodes) and 50 controls aged 2-4 years. Saliva and buccal swaps were used for DNA extraction. Chi square tests were performed on 23 SNPs in 15 genes. Results were expressed in unadjusted odds ratio (OR) with 95% confidence interval. Multiple testing was corrected by the Benjamini and Hochberg False Discovery Rate.

Results: In total 134 boys and 116 girls participated with an average age of 3.3 years. All SNPs had a high call rate (94.0-99.2%). The frequencies of a genetic variant in ADAM33 (rs511898) differed statistically significantly between cases and controls leading to OR=2.4 (1.2-4.9) for CT genotype and OR=1.0 (0.4-2.5) for TT genotype compared to CC genotype (p=0.03). The frequencies of a genetic variant in ORMLD3 (rs7216389) differed statistically significant between cases and controls leading to OR=3.7 (1.7-8.2) for CT genotype and OR=2.7 (1.2-6.3) for TT genotype compared to CC genotype (p<0.01). Neither remained statistically significant after multiple testing correction (rs511898 p=0.36, rs7216389 p=0.07).

Conclusions: We observed some evidence for the association of the ORMDL3 SNP rs7216389 and recurrent wheeze. The T-allele was more frequent in recurrent wheezers, which is consistent with previous studies in asthma.
Response of AIDS-related plasmablastic lymphoma (PBL) to bortezomib
Authors: P. Bose, C. L. Thompson, D. G. Gandhi, B. S. Ghabach, H. Ozer
Journal: Journal of Clinical Oncology (2009)

e19562 PBL are a group of highly aggressive neoplasms originally described in the oral cavity and jaws of HIV-infected patients. An AIDS-defining illness, PBL comprises 2.6% of AIDS-related lymphomas. PBL are best distinguished by their unique immunophenotype. They are terminally differentiated B-cell neoplasms, and typically lack common B-cell markers but uniformly express plasma cell markers. We report the first case of PBL that responded to bortezomib. A 42-year-old male with newly diagnosed AIDS presented with nausea, vomiting, bloody diarrhea and epigastric pain. EGD with biopsy revealed a high-grade PBL of the stomach. Flow cytometry was negative for CD45 and all common epithelial, T-cell and B-cell markers, but was positive for CD138 and p63(VS38c). Karyotyping revealed t(8;14), amongst other abnormalities. PET/CT showed significant hypermetabolism in multiple thoracic and abdominal lymph nodes, the left lung, liver and several bones. The diagnosis was stage IVBE PBL. Highly active anti-retroviral therapy was begun. Anthracycline-based chemotherapy was avoided due to persistent hyperbilirubinemia. Bortezomib was then administered at a dose of 1.3 mg/m2 IV on days 1, 4, 8 and 11. PET/CT on day 7 showed a marked decrease in hypermetabolism after only 2 doses, signifying a dramatic treatment response. After a total of 4 doses of bortezomib, he unfortunately succumbed to severe septic shock before a repeat PET/CT could be obtained. The prognosis of PBL is poor, with a median survival of about 6 months in most series. The WHO classifies PBL as a variant of diffuse large B-cell lymphoma. Accordingly, CHOP and CHOP-like regimens have mostly been used. However, studies of their immunophenotype and molecular histogenesis suggest that PBL are more closely related to plasma cell neoplasms. Bortezomib is a proteasome inhibitor widely used in multiple myeloma and mantle cell lymphoma. We chose bortezomib based on our patient's poor performance status and immune function, the desire to avoid combination chemotherapy, and translocations involving the immunoglobulin heavy chain gene locus (8;14) similar to those seen in multiple myeloma(4;14, 14;16) and mantle cell lymphoma(11;14). A shift in the paradigm of treatment of PBL towards agents effective in plasma cell malignancies may be necessary. [Table: see text]
Comparative Studies on Visna, Progressive Pneumonia, and Rous Sarcoma Viruses by Electron Microscopy
Authors: K. K. Takemoto, T. Aoki, C. Garon, M. M. Sturm
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Comparative Studies on Visna, Progressive Pneumonia, and Rous Sarcoma Viruses by Electron Microscopy Get access K. K. Takemoto, K. K. Takemoto Search for other works by this author on: Oxford Academic PubMed Google Scholar T. Aoki, T. Aoki Search for other works by this author on: Oxford Academic PubMed Google Scholar C. Garon, C. Garon Search for other works by this author on: Oxford Academic PubMed Google Scholar M. M. Sturm M. M. Sturm Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 50, Issue 2, February 1973, Pages 543–547, https://doi.org/10.1093/jnci/50.2.543 Published: 01 February 1973 Article history Received: 13 October 1972 Accepted: 22 October 1972 Published: 01 February 1973
Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients
Authors: Myron Zhang, Bryanna Gulotta, Alissa Thomas, Thomas Kaley, Sasan Karimi, Igor Gavrilovic, Kaitlin M. Woo, Zhigang Zhang, Julio Arevalo-Perez, Andrei I. Holodny, Marc Rosenblum, Robert J. Young
Journal: Neuro-Oncology (2015)

Glioblastomas treated with bevacizumab may develop low-signal apparent diffusion coefficient (low-ADC) lesions, which may reflect increased tumor cellularity or atypical necrosis. The purpose of this study was to examine the relationship between low-ADC lesions and overall survival (OS). We hypothesized that growing low-ADC lesions would be associated with shorter OS.We retrospectively identified 52 patients treated with bevacizumab for the first (n = 42, 81%) or later recurrence of primary glioblastoma, who had low-ADC lesions and 2 post-bevacizumab scans ≤90 days apart. Low-ADC lesion volumes were measured, and normalized 5th percentile histogram low-ADC values were recorded. Using OS as the primary endpoint, semiparametric Cox models were fitted to ascertain univariate and multivariate hazard ratios (HRs) with significance at P = .05.Median OS was 9.1 months (95% CI = 7.2-14.3). At the second post-bevacizumab scan, the volume of the low-ADC lesion (median: 12.94 cm(3)) was inversely associated with OS, with larger volumes predicting shorter OS (HR = 1.014 [95% CI = 1.003-1.025], P = .009). The percent change in low-ADC volume (median: 6.8%) trended toward increased risk of death with growing volumes (P = .08). Normalized 5th percentile low-ADC value and its percent change were not associated with OS (P > .51). Also correlated with shorter OS were the pre-bevacizumab nonenhancing volume (P = .025), the first post-bevacizumab enhancing volume (P = .040), and the second post-bevacizumab enhancing volume (P = .004).The volume of low-ADC lesions at the second post-bevacizumab scan predicted shorter OS. This suggests that low-ADC lesions may be considered important imaging markers and included in treatment decision algorithms.
From the Museum: the Art of Thinking. Part Seven: Perspective
Authors: Tom Kotsimbos
Journal: European Respiratory Journal (2014)

Les Demoiselles d'Avignon was an explosion of intuitive creativity that took a quantum leap forward in reshaping our perspective of art and the modern world. Picasso's Demoiselles proclaimed the future as they echoed the monumental nudes and mythical forms of the past. It was a painting that was "destroyed" before it was "created"; analysed as deconstruction before synthesised into something completely new (rivalling the Renaissance in its novel approach to perspective); and as individual and precocious in its execution as multi-dimensional in the forces that shaped it. Five heroic, sharply stylised nudes whose planar shapes exude the primitive dissonant power of forms are crowned by magnetic heads that stare straight at us through angular eyes and medusa-like faces. Their bodies dramatically confront us even though they are rigidly suspended in their surroundings – a fused hardness that contrasts with the transitoriness of impressionism. There is no stillness: no fixed focal point or single source of light; and no floor, horizon or uniform sense of depth. The integrity of mass as distinct from space has now been fragmented as dissected anatomies give us multiple perspectives simultaneously. Muted colour further emphasises form whilst use of the full colour spectrum (pink hued contours of the nudes set off by icy blue panes) allows for an alternative interpretation of depth perspective.
Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial
Authors: Steven J Russell, Mallory A Hillard, Courtney Balliro, Kendra L Magyar, Rajendranath Selagamsetty, Manasi Sinha, Kerry Grennan, Debbie Mondesir, Laya Ekhlaspour, Hui Zheng, Edward R Damiano, Firas H El-Khatib
Journal: The Lancet Diabetes & Endocrinology (2016)